GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity,…
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity,…
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the…
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”…
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Based on positive feedback provided by FDA on key clinical design details Jasper plans to…
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a…
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage…
FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or…
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022…
Industry Seasoned Executive Joins Cytek FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences,…
WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a…
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) — ProKidney LP (ProKidney), a leading clinical-stage cellular…
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical…
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor…
Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing…
London, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) — Virax Biolabs Group Limited (“Virax” or…